Not yet recruiting
Retinal dystrophy
Not yet recruitingSafety and early effectiveness study of VG801 subretinal injection in patients with ABCA4 mutation-associated retinal dystrophy
InvestigationalNo placebo
Safety and early effectiveness study of VG801 subretinal injection in patients with ABCA4 mutation-associated retinal dystrophy
InvestigationalNo placebo
- Disease:Retinal dystrophy
- Substances:VG801-1VG801-2
Countries:
Germany
Germany- Participants:0–17 years · 18–64 years
- Substances:VG801-1
- Sponsor:VeonGen Therapeutics GmbH
